Doxycycline for Acne

Overseen by Raja K Sivamani, MD MS CAT

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: University of California, Davis

No Placebo Group

Approved in 5 Jurisdictions

Trial Summary

What is the purpose of this trial?

Lipidome and microbiome analysis in subjects with acne on doxycycline. Investigators will look at the skin lipidome, blood lipidome, gut micro biome and skin micro biome. Investigators will look at the changes between acne subjects and control participants, but also the changes that occur after the use of antibiotics and how this is altered.

Research Team

Raja K Sivamani, MD MS CAT

Principal Investigator

UCDavis

Eligibility Criteria

This trial is for individuals aged 15 and older who have acne diagnosed by a dermatologist and are prescribed or eligible for Doxycycline. They must understand the study procedures and consent forms. Excluded are those with certain chronic diseases, recent antibiotic use, allergies to tetracyclines, high BMI, or on specific medications.

Inclusion Criteria

Subjects/parents/legal guardian is able to read and comprehend study procedure and consent forms.

I am 15 years old or older.

I am currently taking or am eligible to take Doxycycline for my acne.

Exclusion Criteria

I have not taken isotretinoin in the last six weeks.

I have seborrheic dermatitis, rosacea, or polycystic ovary syndrome.

I have recently started or changed my birth control pill.

Treatment Details

Interventions

• Doxycycline (Antibiotic)

Trial Overview The study examines how Doxycycline affects the lipidome (fats in blood and skin) and microbiome (bacteria in gut and skin) of people with acne compared to controls without treatment. It aims to understand changes due to antibiotics in these biological profiles.

Participant Groups

Group I: doxycycline Experimental Treatment 1 Intervention

Given doxycycline and assessment of gut, blood and skin

Group II: Control Active Control 1 Intervention

Control subjects to assess if there is baseline difference in these micro-evironments.

Doxycycline is already approved in Canada, Japan for the following indications:

Approved in Canada as Doxycycline for:

• Acne
• Bacterial infections
• Chlamydia
• Gonorrhea
• Lyme disease
• Malaria
• Pneumonia
• Rosacea
• Urinary tract infections

Approved in Japan as Doxycycline for:

• Acne
• Bacterial infections
• Chlamydia
• Gonorrhea
• Lyme disease
• Malaria
• Pneumonia
• Rosacea
• Urinary tract infections

Who Is Running the Clinical Trial?

University of California, Davis

Lead Sponsor

Trials

958

Recruited

4,816,000+

Rakesh Dixit

University of California, Davis

Chief Executive Officer since 2024

PhD in Biochemistry and Molecular Biology from the University of California, Davis

Suresh Mahabhashyam

University of California, Davis

Chief Medical Officer since 2020

MD from Bangalore Medical College